133 results on '"Vergara, Ander"'
Search Results
2. Pilot monitoring study in patients with diabetic kidney disease using NORA application
3. Estudio piloto de seguimiento en pacientes con enfermedad renal diabética mediante la aplicación NORA
4. #1022 Vulnerability in onconephrology: women and people who live alone are at greater risk of depression and anxiety
5. WCN24-1319 CIRCULATING ACE2 ACTIVITY IS ELEVATED IN SEVERE COVID-19
6. WCN24-2406 Vulnerability in Onconephrology: Women and people who live alone are at greater risk of depression and anxiety
7. WCN24-1330 EFFECTS OF SGLT2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS ON TOP OF RAS BLOCKADE IN UNINEFRECTOMIZED DB/DB MICE
8. WCN24-647 MONITORING DIABETIC KIDNEY DISEASE USING THE NORA MOBILE APP. PILOT STUDY RESULTS
9. Stimulating cardiac glucose oxidation lessens the severity of heart failure in aged female mice
10. #5710 CHARACTERIZATION OF RESPONSE TO TREATMENT WITH RITUXIMAB IN PATIENTS WITH PRIMARY GLOMERULOPATIES
11. Epidemiology of Immune-Mediated Glomerulopathies before and after SARS-CoV-2 Vaccination: A Tertiary Referral Hospital Experience
12. Endothelin Receptor Antagonists in Kidney Disease
13. Corrigendum: Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
14. Estudio Piloto De Seguimiento En Pacientes Con Enfermedad Renal Diabética Mediante La Aplicación Nora
15. The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy
16. Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice
17. Enteric Budesonide in Transplant and Native IgA Nephropathy: Real-World Clinical Practice
18. Urinary angiotensin-converting enzyme 2 and metabolomics in COVID-19-mediated kidney injury
19. MO631: Diabetic Retinopathy and/or Diabetic Nephropathy Confers A Worse Renal Prognosis
20. MO154: Enteric Budesonide in IGAN Nephropathy: A Real World Clinical Practice
21. MO628: A Clinical Score for Identifying Non-Diabetic Nephropathy in Patients with Diabetes and Kidney Disease
22. Urinary angiotensin-converting enzyme 2 and metabolomics in COVID-19-mediated kidney injury.
23. COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?
24. Safety of Obtaining an Extra Biobank Kidney Biopsy Core
25. Antioxidant Roles of SGLT2 Inhibitors in the Kidney
26. Evaluation of SARS-CoV-2 entry, inflammation and new therapeutics in human lung tissue cells
27. Apelin pathway in cardiovascular, kidney, and metabolic diseases: Therapeutic role of apelin analogs and apelin receptor agonists
28. Focal and segmental glomerulosclerosis associated with COVID-19 infection
29. Human lung for the study of SARS-CoV-2
30. Focal and segmental glomerulosclerosis associated with COVID-19 infection
31. Glomeruloesclerosis focal y segmentaria asociada a infección por COVID-19
32. The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19
33. How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR
34. Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model
35. A Specific Tubular ApoA-I Distribution Is Associated to FSGS Recurrence after Kidney Transplantation
36. MO298A SPECIFIC TUBULAR APOA-I DISTRIBUTION IS ASSOCIATED TO FSGS RECURRENCE AFTER KIDNEY TRANSPLANTATION
37. MO178DOES OBTAINING AN EXTRA CORE KIDNEY BIOPSY FOR RESEARCH PURPOSES INCREASE THE RISK OF COMPLICATIONS? A SINGLE CENTER EXPERIENCE
38. MO308COULD THE PRESENCE OF ANCAS IN IGA NEPHROPATHY WITH CRESCENTS HAVE A CLINICAL IMPLICATION?
39. Evaluation of SARS-CoV-2 Entry, Inflammation and New Therapeutics in Human Lung Tissue Cells
40. A Nephrologist Perspective on Obesity: From Kidney Injury to Clinical Management
41. COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease
42. Matrix Metalloproteinases in Diabetic Kidney Disease
43. Challenges in primary focal segmental glomerulosclerosis diagnosis : from the diagnostic algorithm to novel biomarkers
44. Sodium-glucose cotransporter 2 inhibition : towards an indication to treat diabetic kidney disease
45. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers
46. Revisiting Experimental Models of Diabetic Nephropathy
47. Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
48. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
49. Sodium-glucose cotransporter inhibitors: beyond glycaemic control
50. Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.